A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 14194 participants.
Also called NCT05754957
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 14,194 participants
- Registry
-
NCT05754957 -
2022-501418-69-00
-
- Other papers using this trial's data
- Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, North Macedonia, Philippines, Poland, Portugal, Romania, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Switzerland, Taiwan, Thailand, Türkiye, United Kingdom, Vietnam
- Registry status
- Completed
Technical summary
Registry record NCT05754957. Randomized; quadruple masking; primary purpose treatment. Start 2023-04-07 (actual); primary completion 2026-02-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
- Acronym
- LIBREXIA-ACS
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- Milvexian
- Intervention (Other)
- Placebo
- Lead sponsor
- Janssen Research & Development, LLC
- Collaborator
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct05754957- Content hash
314cb5e5ac5fac04cdd8c9a0d63f7a9482af4a2768508b32826a7df2fff4dbcf